Serum metabolic profiling in inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 57, Issue 8, 2012, Pages 2157-2165

  Williams, Horace R T ^a   Willsmore, James D ^a   Cox, I Jane ^b   Walker, David G ^a   Cobbold, Jeremy F L ^a   Taylor Robinson, Simon D ^a   Orchard, Timothy R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF HEPATOLOGY   (United Kingdom)

Author keywords

Crohn's disease; Inflammatory bowel disease; Metabolic profiling; Metabolomics; Metabonomics; Ulcerative colitis

Indexed keywords

CHOLINE; LIPID;

ACCURACY; ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CROHN DISEASE; DISCRIMINANT ANALYSIS; ENTERITIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTIVARIATE ANALYSIS; PARTIAL LEAST SQUARES DISCRIMINANT ANALYSIS; PATHOGENESIS; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SERUM; SPECTROMETER; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; METABOLOME; MIDDLE AGED; YOUNG ADULT;

EID: 84866353478     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2127-2     Document Type: Article

References (53)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
2. Shih DQ, Targan SR. Insights into IBD pathogenesis. Curr Gastroenterol Rep. 2009;11:473-480.
3. Nicholson JK, Lindon JC, Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.
4. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Natl Rev Microbiol. 2005;3:431-438.
5. Williams HR, Cox IJ, Walker DG, et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol. 2009;104:1435-1444.
6. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546-551.
7. Jansson J, Willing B, Lucio M, et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS ONE. 2009;4:e6386.
8. Bjerrum JT, Nielsen OH, Hao F, et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res. 2010;9:954-962.
9. Bezabeh T, Somorjai RL, Smith IC, Nikulin AE, Dolenko B, Bernstein CN. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. Am J Gastroenterol. 2001;96:442-448.
10. Lin HM, Helsby NA, Rowan DD, Ferguson LR. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:1021-1029.
11. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67:793-811.
12. Teahan O, Gamble S, Holmes E, et al. Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal Chem. 2006;78:4307-4318.
13. Bertini I, Calabro A, De Carli V, et al. The metabonomic signature of celiac disease. J Proteome Res. 2009;8:170-177.
14. Lauridsen MB, Bliddal H, Christensen R, et al. 1H NMR spectroscopy- based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res. 2010;9: 4545-4553.
15. MacIntyre DA, Jimenez B, Lewintre EJ, et al. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia. 2010;24:788-797.
16. Martin FP, Rezzi S, Philippe D, et al. Metabolic assessment of gradual development of moderate experimental colitis in IL-10- deficient mice. J Proteome Res. 2009;8:2376-2387.
17. Chen C, Shah YM, Morimura K, et al. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab. 2008;7:135-147.
18. Stange EF, Travis SP, Vermeire S, et al. European evidencebased consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55:i1-i15.
19. Stange EF, Travis SP, Vermeire S, et al. European evidencebased consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1-23.
20. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19:5-36.
21. Lenz EM, Bright J, Wilson ID, et al. A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal. 2003;33:1103-1115.
22. O'Sullivan A, Gibney MJ, Brennan L. Dietary intake patterns are reflected in metabolomic profiles: potential role in dietary assessment studies. Am J Clin Nutr. 2011;93:314-321.
23. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
24. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29-32.
25. Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic Acids Res. 2007;35:D521-D526.
26. Holmes E, Tsang TM, Huang JT, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006;3:e327.
27. Sussulini A, Prando A, Maretto DA, et al. Metabolic profiling of human blood serum from treated patients with bipolar disorder employing 1H NMR spectroscopy and chemometrics. Anal Chem. 2009;81:9755-9763.
28. Mao H, Wang H, Wang B, et al. Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach. J Proteome Res. 2009;8:5423-5430.
29. Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS models. J Chemomet. 2008;22:594-600.
30. Kochhar S, Jacobs DM, Ramadan Z, Berruex F, Fuerholz A, Fay LB. Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Anal Biochem. 2006;352:274-281.
31. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut. 2004;53:1806-1812.
32. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
33. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
34. Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007;13:727-732.
35. Friedman G, Barak V, Chajek-Shaul T, et al. Recombinant human interleukin-1 suppresses lipoprotein lipase activity, but not expression of lipoprotein lipase mRNA in mesenchymal rat heart cell cultures. Biochim Biophys Acta. 1991;1089:83-87.
36. Querfeld U, Ong JM, Prehn J, et al. Effects of cytokines on the production of lipoprotein lipase in cultured human macrophages. J Lipid Res. 1990;31:1379-1386.
37. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37: 693-707.
38. Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980-988.
39. Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71:807-815.
40. Hyka N, Dayer JM, Modoux C, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factoralpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood. 2001;97:2381-2389.
41. Zeisel SH, Blusztajn JK. Choline and human nutrition. Ann Rev Nutr. 1994;14:269-296.
42. NassifA, LongoWE,Mazuski JE, VernavaAM, KaminskiDL.Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy. Dis Colon Rectum. 1996;39: 217-223.
43. Niculescu MD, Da Costa KA, Fischer LM, Zeisel SH. Lymphocyte gene expression in subjects fed a low-choline diet differs between those who develop organ dysfunction and those who do not. Am J Clin Nutr. 2007;86:230-239.
44. Zeisel SH. Is there a new component of the Mediterranean diet that reduces inflammation? Am J Clin Nutr. 2008;87:277-278.
45. Mehta AK, Singh BP, Arora N, Gaur SN. Choline attenuates immune inflammation and suppresses oxidative stress in patients with asthma. Immunobiology. 2010;215:527-534.
46. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
47. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
48. Lanfranchi GA, Brignola C, Campieri M, et al. Assessment of nutritional status in Crohn's disease in remission or low activity. Hepatogastroenterology. 1984;31:129-132.
49. Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep. 1999;1:410-416.
50. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
51. Velagapudi VR, Hezaveh R, Reigstad CS, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010;51:1101-1112.
52. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480-484.
53. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulinresistant mice. Proc Natl Acad Sci USA. 2006;103:12511-12516.